Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 16, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021 .
View HTML
Toggle Summary Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 15, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM ) platform.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi)
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
Conference Call and Webcast Today, February 4 at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Feb. 4, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2020 . The company is hosting a conference call at 4:30
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 19, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 4, 2021 , at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2020 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 7, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 4, 2020 , the Compensation Committee of the Board of Directors approved “inducement” grants to 27 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 30, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 32 nd Annual Virtual Healthcare Conference – December 1-3, 2020 December 2, 2020 –   Chris Anzalone
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020 , has now closed.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
- Conference Call and Webcast Today, November 23 at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020 . The company is hosting a conference call at 4:30 p.m.
View HTML